489 related articles for article (PubMed ID: 29320474)
21. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
Zhao R; Song Y; Wang Y; Huang Y; Li Z; Cui Y; Yi M; Xia L; Zhuang W; Wu X; Zhou Y
Cell Prolif; 2019 May; 52(3):e12571. PubMed ID: 30714229
[TBL] [Abstract][Full Text] [Related]
22. High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment.
Sánchez-Magraner L; Miles J; Baker CL; Applebee CJ; Lee DJ; Elsheikh S; Lashin S; Withers K; Watts AG; Parry R; Edmead C; Lopez JI; Mehta R; Italiano A; Ward SG; Parker PJ; Larijani B
Cancer Res; 2020 Oct; 80(19):4244-4257. PubMed ID: 32855204
[TBL] [Abstract][Full Text] [Related]
23. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
[TBL] [Abstract][Full Text] [Related]
24. Association of combined PD-L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma.
Bence C; Hofman V; Chamorey E; Long-Mira E; Lassalle S; Albertini AF; Liolios I; Zahaf K; Picard A; Montaudié H; Lacour JP; Passeron T; Andea AA; Ilie M; Hofman P
J Eur Acad Dermatol Venereol; 2020 May; 34(5):984-994. PubMed ID: 31625630
[TBL] [Abstract][Full Text] [Related]
25. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
26. Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model.
Padrón Á; Hurez V; Gupta HB; Clark CA; Pandeswara SL; Yuan B; Svatek RS; Turk MJ; Drerup JM; Li R; Curiel TJ
Exp Gerontol; 2018 May; 105():146-154. PubMed ID: 29326088
[TBL] [Abstract][Full Text] [Related]
27. Acral Melanoma Is Infiltrated with cDC1s and Functional Exhausted CD8 T Cells Similar to the Cutaneous Melanoma of Sun-Exposed Skin.
De Leon-Rodríguez SG; Aguilar-Flores C; Gajón JA; Mantilla A; Gerson-Cwilich R; Martínez-Herrera JF; Rodríguez-Soto BE; Gutiérrez-Quiroz CT; Pérez-Koldenkova V; Muñoz-Cruz S; Bonifaz LC; Fuentes-Pananá EM
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902214
[TBL] [Abstract][Full Text] [Related]
28. CD103
Edwards J; Wilmott JS; Madore J; Gide TN; Quek C; Tasker A; Ferguson A; Chen J; Hewavisenti R; Hersey P; Gebhardt T; Weninger W; Britton WJ; Saw RPM; Thompson JF; Menzies AM; Long GV; Scolyer RA; Palendira U
Clin Cancer Res; 2018 Jul; 24(13):3036-3045. PubMed ID: 29599411
[No Abstract] [Full Text] [Related]
29. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
30. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Daud AI; Wolchok JD; Robert C; Hwu WJ; Weber JS; Ribas A; Hodi FS; Joshua AM; Kefford R; Hersey P; Joseph R; Gangadhar TC; Dronca R; Patnaik A; Zarour H; Roach C; Toland G; Lunceford JK; Li XN; Emancipator K; Dolled-Filhart M; Kang SP; Ebbinghaus S; Hamid O
J Clin Oncol; 2016 Dec; 34(34):4102-4109. PubMed ID: 27863197
[TBL] [Abstract][Full Text] [Related]
31. CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade.
Chen L; Diao L; Yang Y; Yi X; Rodriguez BL; Li Y; Villalobos PA; Cascone T; Liu X; Tan L; Lorenzi PL; Huang A; Zhao Q; Peng D; Fradette JJ; Peng DH; Ungewiss C; Roybal J; Tong P; Oba J; Skoulidis F; Peng W; Carter BW; Gay CM; Fan Y; Class CA; Zhu J; Rodriguez-Canales J; Kawakami M; Byers LA; Woodman SE; Papadimitrakopoulou VA; Dmitrovsky E; Wang J; Ullrich SE; Wistuba II; Heymach JV; Qin FX; Gibbons DL
Cancer Discov; 2018 Sep; 8(9):1156-1175. PubMed ID: 30012853
[TBL] [Abstract][Full Text] [Related]
32. Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis.
Wrede N; Hoffmann I; Vollbrecht C; Koch I; Wolkenstein P; Klauschen F; Capper D; von Laffert M; Jurmeister P
Pathol Res Pract; 2022 Jan; 229():153689. PubMed ID: 34844086
[TBL] [Abstract][Full Text] [Related]
33. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Goodman AM; Kato S; Bazhenova L; Patel SP; Frampton GM; Miller V; Stephens PJ; Daniels GA; Kurzrock R
Mol Cancer Ther; 2017 Nov; 16(11):2598-2608. PubMed ID: 28835386
[TBL] [Abstract][Full Text] [Related]
34. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
Twyman-Saint Victor C; Rech AJ; Maity A; Rengan R; Pauken KE; Stelekati E; Benci JL; Xu B; Dada H; Odorizzi PM; Herati RS; Mansfield KD; Patsch D; Amaravadi RK; Schuchter LM; Ishwaran H; Mick R; Pryma DA; Xu X; Feldman MD; Gangadhar TC; Hahn SM; Wherry EJ; Vonderheide RH; Minn AJ
Nature; 2015 Apr; 520(7547):373-7. PubMed ID: 25754329
[TBL] [Abstract][Full Text] [Related]
35. PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer.
Bocanegra A; Fernandez-Hinojal G; Zuazo-Ibarra M; Arasanz H; Garcia-Granda MJ; Hernandez C; Ibañez M; Hernandez-Marin B; Martinez-Aguillo M; Lecumberri MJ; Fernandez de Lascoiti A; Teijeira L; Morilla I; Vera R; Escors D; Kochan G
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30986912
[TBL] [Abstract][Full Text] [Related]
36. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.
Homet Moreno B; Zaretsky JM; Garcia-Diaz A; Tsoi J; Parisi G; Robert L; Meeth K; Ndoye A; Bosenberg M; Weeraratna AT; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Ribas A
Cancer Immunol Res; 2016 Oct; 4(10):845-857. PubMed ID: 27589875
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.
Diana A; Wang LM; D'Costa Z; Allen P; Azad A; Silva MA; Soonawalla Z; Liu S; McKenna WG; Muschel RJ; Fokas E
Oncotarget; 2016 Jul; 7(27):40992-41004. PubMed ID: 27329602
[TBL] [Abstract][Full Text] [Related]
38. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
[TBL] [Abstract][Full Text] [Related]
39. Nodular primary cutaneous melanoma is associated with PD-L1 expression.
Giavina-Bianchi M; Giavina-Bianchi P; Sotto MN; Rodig S; Mihm M; Festa Neto C; Duncan LM; Kalil J
Eur J Dermatol; 2020 Aug; 30(4):352-357. PubMed ID: 32969795
[TBL] [Abstract][Full Text] [Related]
40. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.
Thompson ED; Zahurak M; Murphy A; Cornish T; Cuka N; Abdelfatah E; Yang S; Duncan M; Ahuja N; Taube JM; Anders RA; Kelly RJ
Gut; 2017 May; 66(5):794-801. PubMed ID: 26801886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]